| Extensive CRISPR RNA modification reveals chemical compatibility and structure-activity relationships for Cas9 biochemical activity D O’Reilly, ZJ Kartje, EA Ageely, E Malek-Adamian, M Habibian, ... Nucleic Acids Research 47 (2), 546-558, 2019 | 78 | 2019 |
| Activation of frataxin protein expression by antisense oligonucleotides targeting the mutant expanded repeat L Li, X Shen, Z Liu, M Norrbom, TP Prakash, D O'Reilly, VK Sharma, ... nucleic acid therapeutics 28 (1), 23-33, 2018 | 36 | 2018 |
| Rationally designed anti-CRISPR nucleic acid inhibitors of CRISPR-Cas9 CL Barkau, D O'Reilly, KJ Rohilla, MJ Damha, KT Gagnon nucleic acid therapeutics 29 (3), 136-147, 2019 | 31 | 2019 |
| Activating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion X Shen, A Kilikevicius, D O'Reilly, TP Prakash, MJ Damha, F Rigo, ... Bioorganic & medicinal chemistry letters 28 (17), 2850-2855, 2018 | 22 | 2018 |
| Mechanochemical synthesis of short DNA fragments JD Thorpe, D O'Reilly, T Friščić, MJ Damha Chemistry–A European Journal 26 (41), 8857-8861, 2020 | 20 | 2020 |
| Exploring atypical fluorine–hydrogen bonds and their effects on nucleoside conformations D O'Reilly, RS Stein, MB Patrascu, SK Jana, J Kurian, N Moitessier, ... Chemistry–A European Journal 24 (61), 16432-16439, 2018 | 17 | 2018 |
| Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection VN Hariharan, M Shin, CW Chang, D O’Reilly, A Biscans, K Yamada, ... Proceedings of the National Academy of Sciences 120 (11), e2219523120, 2023 | 13 | 2023 |
| Next-Generation Peptide Nucleic Acid Chimeras Exhibit High Affinity and Potent Gene Silencing AJ Debacker, VK Sharma, P Meda Krishnamurthy, D O’Reilly, R Greenhill, ... Biochemistry 58 (6), 582-589, 2018 | 12 | 2018 |
| Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington’s disease D O'Reilly, J Belgrad, C Ferguson, A Summers, E Sapp, C McHugh, ... Molecular Therapy 31 (6), 1661-1674, 2023 | 11 | 2023 |
| Gene editing with CRISPR-Cas12a guides possessing ribose-modified pseudoknot handles EA Ageely, R Chilamkurthy, S Jana, L Abdullahu, D O’Reilly, PJ Jensik, ... Nature communications 12 (1), 6591, 2021 | 11 | 2021 |
| Small nucleic acids and the path to the clinic for anti-CRISPR CL Barkau, D O'Reilly, SB Eddington, MJ Damha, KT Gagnon Biochemical pharmacology 189, 114492, 2021 | 8 | 2021 |
| The role of patient involvement when developing therapies A Aartsma-Rus, E Vroom, D O'Reilly nucleic acid therapeutics 32 (2), 118-122, 2022 | 3 | 2022 |
| A programmable dual-targeting di-valent siRNA scaffold supports potent multi-gene modulation in the central nervous system J Belgrad, Q Tang, S Hildebrand, A Summers, E Sapp, D Echeverria, ... bioRxiv, 2023 | 1 | 2023 |
| OLIGONUCLEOTIDES FOR SARS-CoV-2 MODULATION A Khvorova, J Watts, Z Kennedy, A Biscans, BM da Cruz Godinho, ... US Patent App. 17/333,839, 2023 | 1 | 2023 |
| Improving oligonucleotide as therapeutics: from design, synthesis, and conformational analysis to gene silencing and gene editing applications D O'Reilly McGill University (Canada), 2019 | 1 | 2019 |
| Oligonucleotides for pms1 modulation A Khvorova, D O'reilly, C Ferguson, J Belgrad US Patent App. 18/142,852, 2024 | | 2024 |
| Oligonucleotides for pms2 modulation A Khvorova, D O'reilly, C Ferguson, J Belgrad US Patent App. 18/142,844, 2024 | | 2024 |
| Exon 53 skipping of the human dystrophin transcript with different chemically modified AONs in a mouse model for Duchenne muscular dystrophy S Engelbeen, D O'Reilly, D Van De Vijver, I Verhaart, M van Putten, ... EUROPEAN JOURNAL OF HUMAN GENETICS 32, 515-516, 2024 | | 2024 |
| Oligonucleotides for atn1 modulation A Khvorova, D O'reilly US Patent App. 18/134,167, 2023 | | 2023 |
| Optimized sirna scaffolds A Khvorova, D O'reilly, VN Hariharan, C Lochmann, D Cooper US Patent App. 18/197,948, 2023 | | 2023 |
Masad J. DamhaDistinguished James McGill ProfessorVerified email at mcgill.ca
